Could a Two-Drug sequence shrink tumors with fewer side effects?
NCT ID NCT04197713
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested two drugs, adavosertib and olaparib, given one after the other in 13 people with advanced solid tumors that had specific DNA repair mutations. The goal was to find the best dose and see if this sequence causes fewer side effects than taking both drugs at once. The study focused on safety and tumor response, but it is too small and early to draw firm conclusions about effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adavosertib and olaparib
- What this could lead to
- If this works, it could point toward a more tolerable way to treat advanced solid tumors with specific genetic mutations by giving two drugs one after the other instead of together.
- What could go wrong
- This is a very early Phase 1 trial with only 13 participants, so results may not apply to larger groups. The main goal is safety and dosing, not yet proving the treatment works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a tracer that hunts unstable iron light up hidden tumors?
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers
- Vaccine trains immune system to hunt down cancer cells
- Gut radiation may revive immunotherapy in resistant cancers